Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28792715 | 0.83 | GAA (0.44) | CA12CA1CA9PSMB8BCL2 | |
| SCHEMBL6811054 | 0.82 | NAMPT (0.54) | CA12CA1CA9PSMB8CYP17A1 | |
| SCHEMBL13055402 | 0.79 | CYP17A1 (0.59) | CA12CA1CA9PSMB8CYP17A1 | |
| SCHEMBL28301470 | 0.79 | MALT1 (0.48) | CA12CA1CA9 | |
| SCHEMBL22450127 | 0.76 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23619661 | 0.74 | SMN1; SMN2 (0.62) | CA12CA1CA9PSMB8CYP17A1 | |
| SCHEMBL20865536 | 0.74 | CYP17A1 (0.68) | CA12CA1CA9PSMB8CYP17A1 | |
| SCHEMBL775002 | 0.74 | NAMPT (0.56) | CA12CA1PSMB8CYP17A1NAMPT | |
| SCHEMBL2099875 | 0.74 | — | — | |
| SCHEMBL7685533 | 0.73 | PTK2 (0.57) | NAMPTHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499620-B1 | METHOD FOR THE PREPARATION OF CIS-4-AMINOTETRAHYDROFURAN-2-CARBOXYLATES | BAYER AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| CN-116903628-A | FGFR2 inhibitors and methods of use | 深圳福沃药业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| CN-1688579-A | Condensed pyridines and pyrimidines with TIE2 (TEK) activity | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | CA12 3768/4885CA1 1702/4885CA9 2239/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | CA12 4828/4885CA1 4076/4885CA9 3640/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | CA12 2966/4885CA1 3435/4885CA9 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.